This profile was last updated on
Is this you? Claim your profile.
(2 Total References)
AutoModel™ and ProteoMine™
Peter Domaille, Ph.D., Joins as Director, Structural BiologySan Diego, CA June 10, 2002 -GeneFormatics, Inc., a drug discovery company utilizing proprietary structural and chemo-proteomics technologies for the development of target-specific drugs, today announced that Peter Domaille, Ph.D., has joined as director, structural biology.Dr. Domaille
brings with him a diverse background in spectroscopy and 24 years of experience in chemical and pharmaceutical research and development.
will oversee the company's internal structural biology programs, as well as the development of the integrated and automated NMR technologies in a joint program between GeneFormatics
and Dr. Gaetano Montelione at Rutgers University
will also direct GeneFormatics' strategic collaborations in structural biology.The collaboration with Bruker AXS Inc.
, Bruker BioSpin Corp.
, and Bruker Daltonics Inc.
is focused on the utilization of state-of-the-art structural biology equipment, including cryoprobe technology incorporated into high field NMR spectrometers, the first of which has already been installed and is operational at GeneFormatics
, headquarters in San Diego.GeneFormatics
has also established a strategic collaboration with Bristol-Myers Squibb
to further the development of next-generation technologies for the experimental determination of three-dimensional protein structures.This collaboration involves the enhancement of GeneFormatics'
proprietary NMR technology and software applications for target and lead identification.Dr. Domaille will lead the Structural Biology team, which focuses on determining the structures of important biological proteins and exploiting structural knowledge to expedite lead discovery based on a functional family approach.Prior to this position, Dr. Domaille was the director of biomolecular NMR at DuPont Pharmaceuticals in Wilmington, DE, where he utilized NMR methods to aid drug discovery.He
has worked on streamlining the process of NMR, including the development of both hardware and software for data collection, processing, and NMR structure determination.Before DuPont Pharmaceuticals, Dr. Domaille held positions at E.I. DuPont du Nemours Research and Development and DuPont Merck Pharmaceutical Research and Development.He is also a well-published author and holds positions as a reviewer for several professional journals including the Journal of American Chemical Society, Biochemistry, Journal of Molecular Biology, Journal of Biomolecular NMR, Journal of Magnetic Resonance. Dr. Domaille received his B.S. and Ph.D. from Monash University, Melbourne, Australia, and completed Postdoctoral work at University of Canterbury, Christchurch, New Zealand, and the University of California, Santa Barbara, Calif.
NMR Technologies Development and Applications for Drug Discovery
Dr. Peter J. Domaille, Du Pont Pharmaceuticals Company